Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
新型活性药物适用于一线化疗后疾病进展的无驱动基因突变的晚期非小细胞肺癌患者
期刊:ESMO Open
影响因子:8.3
doi:10.1136/esmoopen-2016-000118
Manegold, Christian; Adjei, Alex; Bussolino, Federico; Cappuzzo, Federico; Crino, Lucio; Dziadziuszko, Rafal; Ettinger, David; Fennell, Dean; Kerr, Keith; Le Chevalier, Thierry; Leighl, Natasha; Papotti, Mauro; Paz-Ares, Luis; Pérol, Maurice; Peters, Solange; Pirker, Robert; Quoix, Elisabeth; Reck, Martin; Smit, Egbert; Vokes, Everett; van Zandwijk, Nico; Zhou, Caicun
